Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

Abstract

Ansamycin antibiotics, such as 17-allylaminogeldanamycin (17-AAG), bind to Hsp90 and regulate its function, resulting in the proteasomal degradation of a subset of signaling proteins that require Hsp90 for conformational maturation. HER2 is a very sensitive target of these drugs. Ansamycins cause RB-dependent G1 arrest that is associated with loss of D-cyclins via a PI3 kinase, Akt dependent pathway. Downregulation of D-cyclin was due, in part, to loss of Akt expression in response to drug. Moreover, in HER2 overexpressing breast cancer cells, 17-AAG caused rapid inhibition of Akt activity prior to any change in Akt protein. Ansamycins caused rapid degradation of HER2 and a concomitant loss in HER3 associated PI3 kinase activity. This led to a loss of Akt activity, dephosphorylation of Akt substrates, and loss of D-cyclin expression. Introduction into cells of a constitutively membrane bound form of PI3 kinase prevented the effects of the drug on Akt activity and D-cyclins. Thus, in breast cancer cells with high HER2, Akt activation by HER2/HER3 heterodimers is required for D-cyclin expression. In murine xenograft models, non-toxic doses of 17-AAG markedly reduced the expression of HER2 and phosphorylation of Akt and inhibited tumor growth. Thus, pharmacological inhibition of Akt activation is achievable with ansamycins and may be useful for the treatment of HER2 driven tumors.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  • Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P . 1997 Curr. Biol. 7: 261–269

  • Bardelli A, Basile ML, Audero E, Giordano S, Wennstrom S, Menard S, Comoglio PM, Ponzetto C . 1999 Oncogene 18: 1139–1146

  • Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L . 1996 J Clin Oncol 14: 737–744

  • Casamayor A, Morrice NA, Alessi DR . 1999 Biochem J 342: 287–292

  • Czar MJ, Galigniana MD, Silverstein AM, Pratt WB . 1997 Biochemistry 36: 7776–7785

  • Diehl JA, Cheng M, Roussel MF, Sherr CJ . 1998 Genes Dev. 12: 3499–3511

  • Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL . 1995 Science 268: 726–731

  • Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN . 1995 Cell 81: 727–736

  • Gilewski T, Seidman A, Norton L, Hudis C . 2000 Cancer Chemother Pharmacol 46: S23–S26

  • Hellyer NJ, Cheng K, Koland JG . 1998 Biochem J 333: 757–763

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R . 1997 Science 275: 1943–1947

  • Marte BM, Downward J . 1997 Trends Biochem Sci 22: 355–358

  • Mimnaugh EG, Chavany C, Neckers L . 1996 J Biol Chem 271: 22796–22801

  • Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N . 1998 J Biol Chem 273: 29864–29872

  • Munster PN, Basso A, Solit D, Norton L, Rosen N . 2001 Clin Cancer Res 7: 2228–2236

  • Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M, Lin J . 2000 Anticancer Res 20: 407–416

  • Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D . 1999 Oncogene 18: 2241–2251

  • Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ . 1998 J Clin Oncol 16: 2659–2671

  • Penuel E, Martin GS . 1999 Mol Biol Cell 10: 1693–1703

  • Pratt WB . 1998 Proc Soc Exp Biol Med 217: 420–434

  • Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH . 1997 Cell 90: 65–75

  • Sato S, Fujita N, Tsuruo T . 2000 Proc Natl Acad Sci USA 97: 10832–10837

  • Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, Hartl FU . 1996 Proc Natl Acad Sci USA 93: 14536–14541

  • Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM . 1996 Mol Cell Biol 16: 5839–5845

  • Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B . 1997 EMBO J 16: 6151–6161

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . 1987 Science 235: 177–182

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF . 1989 Science 244: 707–712

  • Srethapakdi M, Liu F, Tavorath R, Rosen N . 2000 Cancer Res 60: 3940–3946

  • Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW . 1998 Cell 95: 29–39

  • Stancato LF, Silverstein AM, Owens-Grillo JK, Chow YH, Jove R, Pratt WB . 1997 J Biol Chem 272: 4013–4020

  • Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV . 1997 Nat Genet 15: 356–362

  • Stepanova L, Leng X, Parker SB, Harper JW . 1996 Genes Dev. 10: 1491–1502

  • Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, Kris R, Shiloh Y, Givol D, Schlessinger J . 1988 Cancer Res 48: 1517–1520

  • Vanhaesebroeck B, Alessi DR . 2000 Biochem J 346: Pt 3 561–576

  • Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A . 1995 EMBO J 14: 4267–4275

  • Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF . 2000 Cancer Res 60: 342–349

  • Wennstrom S, Downward J . 1999 Mol Cell Biol 19: 4279–4288

  • Whitesell L, Cook P . 1996 Mol Endocrinol 10: 705–712

  • Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L . 2001 J. Biol. Chem. 276: 3702–3708

Download references

Acknowledgements

We thank J Downward and S Wennstrom for providing the p110-CAAX construct. We thank M Moasser for his helpful discussions and technical assistance. This work was in part supported by the NCI Breast SPORE program grant P50CA68425, grant number CA0951 from the National Cancer Institute and the generous support of the Arlene Taub Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Neal Rosen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basso, A., Solit, D., Munster, P. et al. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21, 1159–1166 (2002). https://doi.org/10.1038/sj.onc.1205184

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205184

Keywords

This article is cited by

Search

Quick links